Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
Vedanta Biosciences Awarded $3.9 Million from CARB-X to Ready VE707 for First-in-Human Study for Prevention of Multidrug-Resistant Infections
Vedanta Biosciences to Present at Upcoming Investor Conferences
